The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Positive topline results demonstrate clinical similarity between AVT03 and the reference biologic, Prolia® (denosumab) Two additional studies comparing the pharmacokinetics, safety, and tolerability ...
Denosumab use was associated with a lower risk for incident diabetes among patients with osteoporosis. Denosumab use is associated with a lower risk for diabetes among patients with osteoporosis, ...
Zoledronic acid and denosumab demonstrated comparable fracture and mortality outcomes among patients with type 2 diabetes and osteoporosis. Zoledronic acid and denosumab demonstrate comparable ...
MedPage Today on MSN
Osteonecrosis of the Jaw: A Rare Side Effect of Osteoporosis Therapy
Some of the most commonly used medications for osteoporosis can lead to osteonecrosis of the jaw (ONJ), a rare but serious ...
REYKJAVIK, Iceland, July 02, 2024 (GLOBE NEWSWIRE) -- Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback